IFNA2 and COVID-19: Critical component of antiviral response (392); significant impairment (low levels) in severe and critical COVID-19 (94, 393); IgG autoantibodies to IFN-α2 (285, 309) may be seen in patients with critical COVID-19 (309) which may persist for at least 2-3 months after infection (285)